Cargando…

A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer

Although nanoliposomal irinotecan combined with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV) has been used to treat first-line resistant unresectable pancreatic cancer, the efficacy and safety data among the elderly remain limited. We retrospectively analyzed clinical outcomes among elderly patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikoma, Tatsuki, Matsumoto, Toshihiko, Boku, Shogen, Yasuda, Tomoyo, Masuda, Masataka, Ito, Takashi, Nakamaru, Koh, Yamaki, So, Nakayama, Shinji, Hashimoto, Daisuke, Yamamoto, Tomohisa, Shibata, Nobuhiro, Ikeura, Tsukasa, Naganuma, Makoto, Satoi, Sohei, Kurata, Takayasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218867/ https://www.ncbi.nlm.nih.gov/pubmed/37240585 http://dx.doi.org/10.3390/jcm12103477

Ejemplares similares

Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit
por: Yamamoto, Tomohisa, et al.
Publicado: (2022)

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
por: Akahori, Takahiro, et al.
Publicado: (2019)

Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma
por: Satoi, Sohei, et al.
Publicado: (2019)

Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail
por: Matsui, Yuki, et al.
Publicado: (2022)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma
por: Yanagimoto, Hiroaki, et al.
Publicado: (2020)

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
por: Takada, Ryoji, et al.
Publicado: (2023)

The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
por: Sakaguchi, Tatsuma, et al.
Publicado: (2020)

Efficacy and safety of endoscopic stent placement for afferent loop obstruction using a short double‐balloon endoscopy
por: Ito, Takashi, et al.
Publicado: (2022)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
por: Ko, Andrew H
Publicado: (2016)

Hepatic actinomycosis after total pancreatectomy: A case report
por: Sakaguchi, Tatsuma, et al.
Publicado: (2021)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Usefulness of half‐covered metallic stent placement in preventing acute cholecystitis complication in pancreatic cancer‐induced distal biliary stricture
por: Takaoka, Makoto, et al.
Publicado: (2020)

Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
por: Allo, Gabriel, et al.
Publicado: (2022)

Prognosis in Patients With Gallbladder Edema Misdiagnosed as Cholecystitis
por: Matsui, Yoichi, et al.
Publicado: (2019)

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
por: Chang, T. C., et al.
Publicado: (2015)

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
por: Glassman, Danielle C., et al.
Publicado: (2018)

Development of Severe Acute Pancreatitis Following Uncovered Metallic Stent Placement: A Rare Case Report
por: Takaoka, Makoto, et al.
Publicado: (2020)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
por: Liang, Barry J., et al.
Publicado: (2020)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

The academic impact and value of an international online surgery lecture series
por: Hashimoto, Daisuke, et al.
Publicado: (2023)

First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Long-term Outcomes after Steroid Pulse Therapy in Patients with Type 1 Autoimmune Pancreatitis
por: Ikeura, Tsukasa, et al.
Publicado: (2023)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Long-Term Survival of a Patient With Peritoneal Carcinomatosis From Pancreatic Cancer Maintained by Nanoliposomal Irinotecan as Third-Line Chemotherapy
por: Nagata, Keiji, et al.
Publicado: (2022)

Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)

Acute median arcuate ligament syndrome after pancreaticoduodenectomy
por: Karabicak, Ilhan, et al.
Publicado: (2016)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
por: Zheng, Jinzi, et al.
Publicado: (2015)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
por: Kobayashi, Satoshi, et al.
Publicado: (2023)

Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
por: Möhring, Christian, et al.
Publicado: (2023)

Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Satoi, Sohei
Publicado: (2021)

5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
por: Yamai, Takuo, et al.
Publicado: (2022)

Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage
por: Yamamoto, Tomohisa, et al.
Publicado: (2018)

Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKCζ immunostaining for detection of reverse polarity
por: Ryota, Hironori, et al.
Publicado: (2021)

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7l95vk3s41dijbrt5ihgqjp2bl